Petrausch Ulf
Onkozentrum Zürich, Swiss Tumor Immunology Institute, Zürich.
Ther Umsch. 2019 Sep;76(4):195-198. doi: 10.1024/0040-5930/a001084.
Immunotherapy - immune-related adverse events and their management Checkpoint-Inhibition has become an important part of modern oncological treatment strategies for many patients with cancer. The development of this new class of anti-cancer drugs has begun for ten years and showed meanwhile a specific new side effect profile. Since the mode of action of checkpoint inhibitors is immune modulation the side effects are particularly different to so far established anti-cancer drugs. Because of the immunological nature of side effects, the spectrum is wide, and the symptoms are amble. Additionally, the side effects can appear at very different time points after the administration of the checkpoint inhibitor. Therefore, the recognition and the management are a new challenge for the care teams. Only if the whole care team is able to understand, diagnose and efficiently manage the side effects the therapeutic potential of this new class of anti-cancer drugs can be made useful for the patients. The article aims to provide information for the care teams to recognize and manage side effects of checkpoint-inhibitors.
免疫疗法——免疫相关不良事件及其管理 检查点抑制已成为许多癌症患者现代肿瘤治疗策略的重要组成部分。这类新型抗癌药物的研发已开展了十年，同时呈现出特定的新副作用特征。由于检查点抑制剂的作用方式是免疫调节，其副作用与迄今已确立的抗癌药物有很大不同。由于副作用的免疫性质，范围广泛，症状多样。此外，副作用可能在给予检查点抑制剂后的非常不同的时间点出现。因此，识别和管理对护理团队来说是一项新挑战。只有整个护理团队能够理解、诊断并有效管理这些副作用，这类新型抗癌药物的治疗潜力才能对患者发挥作用。本文旨在为护理团队提供有关识别和管理检查点抑制剂副作用的信息。
